Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Nucl Med Mol Imaging ; 48(6): 1773-1784, 2021 06.
Article in English | MEDLINE | ID: mdl-33398412

ABSTRACT

PURPOSE: This preclinical study aims to evaluate the extent to which a change in prostate-specific membrane antigen (PSMA) expression of castration-resistant prostate cancer (CRPC) following standard treatment is reflected in [18F]JK-PSMA-7 PET/CT. METHODS: Castrated mice supplemented with testosterone implant were xenografted with human LNCaP CRPC. After appropriate tumour growth, androgen deprivation therapy (ADT) was carried out by the removal of the implant followed by a single injection of docetaxel (400 µg/20-g mouse) 2 weeks later. [18F]JK-PSMA-7 PET/CT were performed before ADT, then before and at days 12, 26, 47 and 69 after docetaxel administration. The [18F]JK-PSMA-7 PET data were compared to corresponding unspecific metabolic [18F]FDG PET/CT and ex vivo quantification of PSMA expression estimated by flow cytometry on repeated tumour biopsies. RESULTS: ADT alone had no early effect on LNCaP tumours that pursued their progression. Until day 12 post-docetaxel, the [18F]JK-PSMA7 uptake was significantly higher than that of [18F]FDG, indicating the persistence of PSMA expression at those time points. From day 26 onwards when the tumours were rapidly expanding, both [18F]JK-PSMA7 and [18F]FDG uptake continuously decreased although the decrease in [18F]JK-PSMA uptake was markedly faster. The fraction of PSMA-positive cells in tumour biopsies decreased similarly over time to reach a non-specific level after the same time period. CONCLUSION: Applying PSMA-based imaging for therapy monitoring in patients with CRPC should be considered with caution since a reduction in [18F]JK-PSMA-7 PET uptake after successive ADT and chemotherapy may be related to downregulation of PSMA expression in dedifferentiated and rapidly proliferating tumour cells.


Subject(s)
Prostatic Neoplasms , Androgen Antagonists , Animals , Fluorodeoxyglucose F18 , Heterografts , Humans , Male , Mice , Positron Emission Tomography Computed Tomography , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/drug therapy
2.
Dalton Trans ; 48(41): 15567-15576, 2019 Oct 22.
Article in English | MEDLINE | ID: mdl-31342987

ABSTRACT

We report several new dyads constituted of cationic iridium(iii) photosensitizers and cobalt(iii) catalyst connected via free pendant pyridine on the photosensitizers. These dyads were studied by X-ray crystallography, electrochemistry, absorption and emission spectroscopy as well as theoretical calculations and were shown to efficiently produce H2 under visible light irradiation. In every case, the dyad outperformed the equivalent system without a pendant pyridine. The dependence between irradiation wavelength and photocatalytic performances was also studied, with H2 being evolved with turn-over numbers up to 295, 251, 188 and 78 molH2 molPS-1 under blue, green, yellow and red light, respectively.

3.
Inorg Chem ; 56(18): 10875-10881, 2017 Sep 18.
Article in English | MEDLINE | ID: mdl-28510431

ABSTRACT

The synthesis of a Ir(III)-Co(III) dyad with vectorial electron transfer afforded a novel supramolecular system that photocatalytically produces hydrogen in a range extending from the blue region of the spectrum to the red region with higher turnover number and frequency compared to other bimetallic dyads.

SELECTION OF CITATIONS
SEARCH DETAIL
...